REG - Circassia Pharma Plc AstraZeneca PLC - Notification of Major Interest in Shares <Origin Href="QuoteRef">AZN.L</Origin> <Origin Href="QuoteRef">CIRCI.L</Origin>

AstraZenecaAnnouncement

12/04/2017 17:35

RNS Number : 3813C
Circassia Pharmaceuticals Plc
12 April 2017



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Circassia Pharmaceuticals plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):


3. Full name of person(s) subject to the
notification obligation:iii
AstraZeneca PLC
4. Full name of shareholder(s)
(if different from 3.):iv
AstraZeneca UK Limited
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
12 April 2017
6. Date on which issuer notified:
12 April 2017 
7. Threshold(s) that is/are crossed or
reached: vi, vii
3% through to 14% (inclusive)
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
Ordinary shares of 0.08 pence
0
0
47,355,417
0
47,355,417
0
14.25%
GB00BJVD3B28

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
N/A





C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx
N/A



Nominal
Delta



Total (A+B+C)
Number of voting rights
Percentage of voting rights
47,355,417
14.25%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
AstraZeneca PLC (parent Company)
AstraZeneca Intermediate Holdings Limited (wholly owned subsidiary of AstraZeneca PLC)
AstraZeneca UK Limited (99.994% owned by AstraZeneca Intermediate Holdings Limited and 0.006% owned by AstraZeneca PLC) - holder of 47,355,417 Ordinary Shares in Circassia Pharmaceuticals plc 

Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease
to hold:
N/A
12. Date on which proxy holder will cease to hold
voting rights:
N/A


13. Additional information:


14. Contact name:
Julien Cotta
15. Contact telephone number:
01865 405560

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLITMFTMBTBBLR